journal
MENU ▼
Read by QxMD icon Read
search

Leukemia Research Reports

journal
https://www.readbyqxmd.com/read/29682446/systemic-lupus-erythematosus-and-myelofibrosis-a-case-report-and-revision-of-literature
#1
F Del Porto, C Tatarelli, A Di Napoli, M Proietta
Blood cytopenia represents one of the diagnostic criteria for systemic lupus erythematosus (SLE) and may occur as the first symptom of the disease. Antibody-mediated peripheral destruction of blood cells is the main cause of cytopenia observed in patients affected by SLE, however, inflammatory anemia, nutritional deficiencies, immunosuppressive therapy and, more rarely, myelofibrosis (MF) have also been documented. In the literature, 45 cases of autoimmune MF (AIMF) and SLE have been previously reported. Here the 46 th case of a 43-year-old female with a SLE and an underhand cytopenia, with a review of the literature...
2018: Leukemia Research Reports
https://www.readbyqxmd.com/read/29556468/unrelated-hla-mismatched-microtransplantation-in-a-patient-with-refractory-secondary-acute-myeloid-leukemia
#2
Nathan Punwani, Noah Merin, Ann Mohrbacher, George Yaghmour, Allison Sano, Laleh Ramezani, Preet M Chaudhary, Giridharan Ramsingh
Microtransplantation (MST), a type of HLA-mismatched allogeneic cellular therapy, is a promising, cellular therapy for acute myeloid leukemia (AML). MST transfuses granulocyte colony-stimulating factor (G-CSF)-mobilized, HLA-mismatched donor peripheral blood stem cells into patients undergoing conventional chemotherapy. MST, using haploidentical donors, has been shown to yield clinical benefit without any permanent marrow engraftment in AML. Consequently, graft-versus-host disease concerns are rendered irrelevant with no need for immunosuppression...
2018: Leukemia Research Reports
https://www.readbyqxmd.com/read/29326868/essential-thrombocytemia-following-immune-thrombocytopenia-with-jak2v617f-mutation
#3
Giovanni Caocci, Sandra Atzeni, Monica Usai, Giorgio La Nasa
JAK2V617F mutation is found in about 60% of cases of essential thrombocytemia (ET) and represents a driving mutation. Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet (PLT) count. So far, only 2 reports described ET following ITP. For the first time we analyzed in a patient the JAK2V617F allele burden at ITP onset occurred 13 years before the ET diagnosis and found the presence of a small clone JAK2V617F positive clone (3%) raised to 27% in the following years. The association of ET and ITP could suggest similar pathogenetic mechanisms that should be further investigated...
2018: Leukemia Research Reports
https://www.readbyqxmd.com/read/29270355/expression-of-a-specific-extracellular-matrix-signature-is-a-favorable-prognostic-factor-in-acute-myeloid-leukemia
#4
Valerio Izzi, Juho Lakkala, Raman Devarajan, Eeva-Riitta Savolainen, Pirjo Koistinen, Ritva Heljasvaara, Taina Pihlajaniemi
Relapse of acute myeloid leukemia (AML) is still dramatically frequent, imposing the need for early markers to quantify such risk. Recent evidence point to a prominent role for extracellular matrix (ECM) in AML, but its prognostic value has not yet been investigated. Here we have investigated whether the expression of a 15-ECM gene signature could be applied to clinical AML research evaluating a retrospective cohort of 61 AML patients and 12 healthy donors. Results show that patients whose ECM signature expression is at least twice as that of healthy donors have considerably longer relapse-free survival, with further stage-specific therapy outcomes...
2018: Leukemia Research Reports
https://www.readbyqxmd.com/read/29264111/alemtuzumab-based-therapy-for-secondary-malignant-histiocytosis-arising-from-pre-b-all
#5
Muhammad Bilal Abid, Karan Wadera, Jenny M Bird, Joya Pawade, David I Marks
•Secondary Malignant Histiocytosis (SMH) is an exceedingly rare, life-threatening condition that invariably occurs in the presence of an underlying monoclonal hematologic disorder. Prognosis of SMH remains dismal and there is no established treatment. •We report a case of a patient who developed SMH during induction chemotherapy for his underlying pre-B-ALL, that caused persistently high fevers and was only diagnosed by a marrow while cytopenic in phase 2 induction. He was treated with alemtuzumab-based therapy that reduced the histiocytic infiltration of the bone marrow from 80% to 15% and made him eligible to undergo T-cell replete allogeneic stem transplantation from his sibling...
2018: Leukemia Research Reports
https://www.readbyqxmd.com/read/29204341/case-report-exome-sequencing-identifies-t-all-with-myeloid-features-as-a-ikzf1-struck-early-precursor-t-cell-malignancy
#6
Marcus C Hansen, Line Nederby, Eigil Kjeldsen, Marianne A Petersen, Hans B Ommen, Peter Hokland
No abstract text is available yet for this article.
2018: Leukemia Research Reports
https://www.readbyqxmd.com/read/29234595/ibrutinib-as-a-bridge-to-transplant-in-high-risk-chronic-lymphocytic-leukemia-a-case-report-and-review-of-the-literature
#7
Arcari Annalisa, Bassi Simona, Pochintesta Lara, Trabacchi Elena, Moroni Carlo Filippo, Rossi Angela, Zanlari Luca, Vallisa Daniele
The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of novel classes of drugs, such as B-cell receptor (BCR)-inhibitors and BCL-2 antagonists. In selected high-risk patients, the choice to start allogeneic hematopoietic stem cell transplantation (alloHCT) or continue these agents is a matter of debate. Furthermore, published data about the impact on the feasibility of alloHCT and the optimal timing of administration are limited. Here we present a case of relapsed TP53 mutated CLL treated with ibrutinib as a bridge to alloHCT, discussing risks and benefits of different treatment options in a "real life" situation...
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/29159035/tumor-lysis-syndrome-tls-following-intrathecal-chemotherapy-in-a-child-with-acute-myelogenous-leukemia-aml
#8
Chana L Glasser
Tumor Lysis Syndrome (TLS) is a well-known complication of induction therapy for hematologic malignancies. It is characterized by rapid breakdown of malignant white blood cells (WBCs) leading to metabolic derangements and serious morbidity if left untreated. Most commonly, TLS is triggered by systemic chemotherapy, however, there have been case reports of TLS following intrathecal (IT) chemotherapy, all in patients with acute lymphoblastic leukemia (ALL)/lymphoma. Here, we report the first case of a patient with acute myelogenous leukemia (AML) who developed TLS following a single dose of IT cytosine arabinoside (Ara-C)...
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/29085772/thinking-about-cns-metastasis-in-cutaneous-lymphoma-analysis-of-existing-data
#9
REVIEW
Yi Yang, Heather Wickless
To determine some of the key clinical features that help prompt clinicians to pursue additional work-up for evaluation of CNS involvement of MF, we conducted a systematic review to better define characteristics, treatments, outcomes, and mortality in these patients. Our analyses indicated that neurologic surveillance after the diagnosis of MF is crucial. Review of systems should include change in mentation, vestibular, and ocular symptoms. Progression to CNS involvement does not always occur in tandem with cutaneous disease burden...
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/28975067/diagnostic-and-therapeutic-implications-of-genetic-heterogeneity-in-myeloid-neoplasms-uncovered-by-comprehensive-mutational-analysis
#10
Sarah M Choi, Ben Goldenson, Lo Ann Peterson, Shira Dinner, Brady L Stein, Amir Behdad
While growing use of comprehensive mutational analysis has led to the discovery of innumerable genetic alterations associated with various myeloid neoplasms, the under-recognized phenomenon of genetic heterogeneity within such neoplasms creates a potential for diagnostic confusion. Here, we describe two cases where expanded mutational testing led to amendment of an initial diagnosis of chronic myelogenous leukemia with subsequent altered treatment of each patient. We demonstrate the power of comprehensive testing in ensuring appropriate classification of genetically heterogeneous neoplasms, and emphasize thoughtful analysis of molecular and genetic data as an essential component of diagnosis and management...
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/28794969/an-unusual-type-of-myeloid-sarcoma-localization-following-myelofibrosis-a-case-report-and-literature-review
#11
Nicola Orofino, Daniele Cattaneo, Cristina Bucelli, Loredana Pettine, Sonia Fabris, Umberto Gianelli, Nicola Stefano Fracchiolla, Agostino Cortelezzi, Alessandra Iurlo
Myeloid Sarcoma (MS) is a rare malignancy that can present as an isolated disease or more frequently in association with or following acute myeloid leukemia or other myeloid neoplasms and rarely following myelofibrosis. Since molecular pathogenesis and prognostic factors of MS are not well understood, its prognosis remains poor even in the era of novel agents and target therapies. We report the case of a patient with MS following myelofibrosis with multiple subcutaneous, cutaneous and muscle localizations; the latter has been reported in the literature as anecdotal...
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/28794968/successful-salvage-chemotherapy-and-allogeneic-transplantation-of-an-acute-myeloid-leukemia-patient-with-disseminated-fusarium-solani-infection
#12
Sheenu Sheela, Sawa Ito, Jeffrey R Strich, Maura Manion, Celina Montemayor-Garcia, Hao-Wei Wang, Karolyn A Oetjen, Kamile A West, Austin J Barrett, Mark Parta, Juan Gea-Banacloche, Steven M Holland, Christopher S Hourigan, Catherine Lai
Disseminated Fusarium infection is associated with high mortality in immunocompromised patients. Patients with acute myeloid leukemia (AML) often have an extended duration of neutropenia during intensive induction chemotherapy, consolidation chemotherapy, and hematopoietic stem cell transplantation (SCT). There is no consensus regarding management of invasive disseminated Fusarium infections in the setting of prolonged neutropenia (Tortorano et al., 2014) [1]. We report a case of disseminated Fusarium in a patient with relapsed AML who underwent successful chemotherapy and haplo-identical allogeneic SCT with administration of granulocyte colony stimulating factor (G-CSF) and granulocyte infusions...
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/28702343/eb-virus-reactivation-triggers-thrombotic-thrombocytopenic-purpura-in-a-healthy-adult
#13
Satoko Oka, Masaharu Nohgawa
Thrombotic thrombocytopenic purpura (TTP) is rare but life-threatening disease, characterized typically by microangiopathic hemolytic anemia (MAHA), profound peripheral thrombocytopenia and severe deficiency in the von Willebrand factor-cleaving prortease ADAMTS13. It has been reported that acquired immune TTP is closely associated with human immunodeficiency virus infection and influenza infection or vaccination. However, it has not been reported to be associated with Epstein Barr Virus infection or reactivation...
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/28462085/cellular-immune-profiling-after-sequential-clofarabine-and-lenalidomide-for-high-risk-myelodysplastic-syndromes-and-acute-myeloid-leukemia
#14
Prachi Jain, Jeffrey Klotz, Neil Dunavin, Kit Lu, Eleftheria Koklanaris, Debbie Draper, Jeanine Superata, Fariba Chinian, Quan Yu, Keyvan Keyvanfar, Susan Wong, Pawel Muranski, A John Barrett, Sawa Ito, Minoo Battiwalla
Patients with high risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) are commonly older with multiple co-morbidities, rendering them unsuitable for intensive induction chemotherapy or transplantation. We report preliminary cellular immune profiling of four cases receiving sequential clofarabine and lenalidomide for high risk MDS and AML in a phase I study. Our results highlight the potential of immune profiling for monitoring immune-modifying agents in high risk MDS and AML.
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/28462084/dexrazoxane-for-cardioprotection-in-older-adults-with-acute-myeloid-leukemia
#15
Pankit Vachhani, Sarah Shin, Jeffrey Baron, James E Thompson, Meir Wetzler, Elizabeth A Griffiths, Evelena P Ontiveros, Edward J Spangenthal, Eunice S Wang
Anthracyclines constitute the backbone of intensive adult acute myeloid leukemia (AML) therapy. Cardiotoxicity is one of its most serious adverse effects, and its incidence increases with cumulative dose. Dexrazoxane is a cardioprotective agent used in conjunction with anthracycline therapy. There is limited data of its usage in adult AML patients. We report the outcomes of six older adults at high risk of anthracycline-induced cardiotoxicity who received dexrazoxane during induction/re-induction therapy. Five had preserved left-ventricular function while two proceeded onto stem-cell transplantation...
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/28462083/low-body-weight-and-body-mass-index-may-be-associated-with-musculoskeletal-pain-following-imatinib-discontinuation-in-chronic-myeloid-leukemia
#16
Seiichiro Katagiri, Tetsuzo Tauchi, Keiko Ando, Seiichi Okabe, Moritaka Gotoh, Kazuma Ohyashiki
It is difficult to predict musculoskeletal pain as a withdrawal syndrome following the discontinuation of imatinib (IM) in patients with chronic myeloid leukemia. We investigated a link between physical size and musculoskeletal pain following IM discontinuation. In total, seven out of 24 patients developed musculoskeletal pain after discontinuing IM. Those with symptoms had a significantly lower body weight (BW) and body mass index (BMI) than those without symptoms. While previous reports indicated that physical size is associated with the pharmacokinetics of IM, our current study suggests that lower BW and BMI may be associated with musculoskeletal pain following IM discontinuation...
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/28462082/on-arsenic-trioxide-in-the-clinical-treatment-of-acute-promyelocytic-leukemia
#17
REVIEW
Peng Zhang
Arsenic is generally considered hypertoxic. However, it has been used in traditional Chinese medicine since ancient times, to treat serious illnesses. Recently, a single dose of arsenic trioxide (As2 O3 ) has been found especially effective in treating acute promyelocytic leukemia (APL). Generally speaking, As2 O3 is a more effective treatment of APL than other, newer medications and has less severe adverse reactions and greater safety.
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/28331798/aspirin-and-risk-of-multiple-myeloma-in-adults-a-systematic-review-and-meta-analysis
#18
REVIEW
Shing Fung Lee, Ting Ying Ng, Frank Chi Sing Wong, Stewart Yuk Tung
Multiple myeloma is a relatively uncommon plasma cell malignancy. Preclinical and clinical studies have suggested that aspirin might modify the risk of multiple myeloma. We performed a systematic review and meta-analysis of studies to examine the association between regular aspirin use and risk of multiple myeloma. Five observational studies including 332,660 adults were evaluated. The pooled estimate had a hazard ratio of 0.90 (95% confidence interval =0.58-1.39; P=0.638). Odds ratios from the two case-control studies were similar...
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/28275540/a-rare-breed-wild-type-braf-and-ighv-expression-in-a-29-year-old-lady-with-classical-hairy-cell-leukemia
#19
Aneesha Hossain, Hind Rafei, Amar Jariwala, Khaled El-Shami
The V600 BRAF mutation has been described as a key mutation in the pathogenesis of classical hairy cell leukemia (c-HCL) cases without expression of a mutant immunoglobulin heavy chain (IgHV). Here we present a rare case of c-HCL with neither V600 BRAF mutation nor the aforementioned IgHV variant successfully treated with cladribine and review the current literature on its use in women of childbearing age/pregnancy.
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/28275539/a-case-of-acute-myeloid-leukemia-with-e6a2-bcr-abl-fusion-transcript-acquired-after-progressing-from-chronic-myelomonocytic-leukemia
#20
Jinjuan Yao, Dan Douer, Lu Wang, Maria E Arcila, Khedoudja Nafa, April Chiu
Philadelphia (Ph) chromosome is a cytogenetic hallmark of chronic myeloid leukemia (CML). Most patients with CML harbor either the e13a2 or e14a2 BCR-ABL fusion product, while a small subset of the cases expresses e1a2 or e19a2 transcripts. We report a patient with chronic myelomonocytic leukemia (CMML), initially Ph chromosome negative at presentation, with rapid disease progression to acute myeloid leukemia (AML) and appearance of Ph chromosome and BCR-ABL e6a2, a very uncommon fusion transcript. The AML was refractory to treatment with subsequent emergence and dominance of a Ph negative leukemic clone...
2017: Leukemia Research Reports
journal
journal
47893
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"